The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Is The Estimated Growth In Market Size Of The Tepezza Market During 2026–2030?
The historical growth is attributable to a greater detection of thyroid eye disease, innovations in monoclonal antibody development, an increase in specialty infusion centers, enhanced awareness of autoimmune ophthalmic disorders, and improved clinical trial outcomes for biologics.
The projected growth during the forecast period is largely driven by an escalating demand for targeted autoimmune therapies, the broadening scope of biologic treatment pipelines, increased investments in the development of drugs for rare diseases, a heightened focus on personalized ophthalmology treatments, and the expanding embrace of outpatient infusion services. Significant trends anticipated in this period encompass the growing adoption of IGF-1R targeted therapies, an increasing application of monoclonal antibodies for autoimmune conditions, a stronger emphasis on biologic treatments tailored to specific diseases, the expansion of specialty drugs administered through infusion, and improvements in patient monitoring during therapy.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20365&type=smp
What Primary Factors Are Fueling The Expansion Of The Tepezza Market?
The tepezza market is anticipated to expand due to the rising occurrence of thyroid diseases. These conditions encompass various ailments impacting the thyroid gland’s structure or function; this gland is located in the neck and is shaped like a butterfly. The rise in thyroid disease incidence stems from multiple factors, notably enhanced diagnostic methods like high-resolution ultrasound and fine-needle aspiration, which enable earlier detection of thyroid abnormalities. Tepezza (teprotumumab) serves as a treatment for thyroid eye disease; it functions by inhibiting the insulin-like growth factor-1 receptor (IGF-1R), thereby lessening inflammation, swelling, and proptosis around the eyes. For example, in September 2025, Cancer Research United Kingdom, a UK-based non-profit organization dedicated to cancer research and patient support, reported projections of approximately 6,600 new thyroid cancer cases annually by 2038-2040. The incidence rates are foreseen to increase by 27%, from about 7.3 cases per 100,000 people per year in 2024-2026 to roughly 9.2 cases per 100,000. Consequently, the growing occurrence of thyroid diseases is propelling the expansion of the tepezza market.
How Is The Tepezza Market Distributed Across Key Segments?
The tepezza market covered in this report is segmented –
1) By Clinical Indication: Thyroid Eye Disease (TED), Orbital Inflammatory Diseases, Inflammatory Ocular Conditions
2) By Route Of Administration: Intravenous, Subcutaneous
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies
4) By End User: Adult, Geriatric
Which Trends Are Contributing To Changes In The Tepezza Market?
Leading companies in the tepezza (teprotumumab-trbw) market are securing regulatory clearances to broaden its approved uses beyond Thyroid Eye Disease (TED). These regulatory approvals represent official permissions granted by health authorities, confirming a drug’s safety, effectiveness, and quality for particular medical applications. For instance, in April 2023, Horizon Therapeutics plc, an Ireland-based biotechnology company, revealed that the FDA had sanctioned a modification to TEPEZZA (teprotumumab-trbw)’s indication language, permitting its administration to patients suffering from Thyroid Eye Disease (TED) irrespective of their disease activity level or how long they have had the condition. This important revision improves treatment accessibility for all suitable TED patients, given that TEPEZZA stands as the sole FDA-approved drug exclusively for this ailment. The authorization is underpinned by evidence from a Phase 4 clinical trial, which showcased TEPEZZA’s effectiveness in alleviating eye bulging in individuals with chronic TED. Tim Walbert, CEO of Horizon, emphasized that this amendment is intended to facilitate prompt access to the therapy, thereby ultimately enhancing patient results.
Who Are The Leading Firms Participating In The Tepezza Market?
Major companies operating in the tepezza market are Amgen Inc.
Access The Complete Tepezza Market Report:
https://www.thebusinessresearchcompany.com/report/tepezza-global-market-report
Which Region Holds The Largest Share In The Tepezza Market?
North America was the largest region in the tepezza market in 2025. The regions covered in the tepezza market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model